Epidemiology
GLP-1 receptor agonists and outcomes in obese or diabetic patients with Lp(a) above 50 mg/dL: a propensity-matched retrospective cohort (Int J Cardiol 2026)
Original title: GLP-1 receptor agonists associated with better cardiovascular outcomes in obese or diabetic patients with elevated Lp(a) levels: A Multicenter retrospective study
A retrospective multicentre cohort of 24,185 adults with Lp(a) above 50 mg/dL and obesity or type 2 diabetes, of whom 3,791 received a GLP-1 receptor agonist; after 1:1 propensity matching (3,310 per arm) and a median follow-up of about two years, GLP-1RA use was associated with lower all-cause mortality (hazard ratio 0.66, 95 percent CI 0.48 to 0.90) and fewer MACE (hazard ratio 0.68, 95 percent CI 0.60 to 0.76), with myocardial infarction, ischaemic stroke and cardiovascular death each reduced. Observational, with the usual residual confounding of a users-versus-non-users design, but a useful signal for the many high-Lp(a) patients who also carry cardiometabolic risk while specific Lp(a) therapy is awaited.
Original abstract
Background: Elevated lipoprotein(a) [Lp(a)] is a well-established, genetically mediated risk factor for atherosclerotic cardiovascular disease (ASCVD), yet effective therapies targeting Lp(a) remain limited. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide cardiometabolic benefits in high-risk populations, but their impact among patients with elevated Lp(a) levels is not well defined.
Methods: We conducted a retrospective cohort study to evaluate cardiovascular outcomes associated with GLP-1RA therapy in adults with Lp(a) >50 mg/dL and comorbid obesity or type 2 diabetes. Patients were categorized into GLP-1RA users versus non-users and matched 1:1 using propensity scores based on demographics, cardiovascular risk factors, and baseline comorbidities. The primary outcome was all-cause mortality; secondary outcomes included major adverse cardiovascular events (MACE: myocardial infarction, ischemic stroke, and coronary revascularization). Hazard ratios (HR) with 95% confidence intervals (CI) were estimated using Cox proportional hazards models.
Results: Among 24,185 eligible patients, 3791 received a GLP-1RA. After matching, 3310 patients remained in each cohort with balanced baseline characteristics. Over a median follow-up of approximately two years, GLP-1RA use was associated with significantly lower all-cause mortality (HR 0.66, 95% CI 0.48-0.90) and reduced MACE (HR 0.68, 95% CI 0.60-0.76). Individual components, including myocardial infarction, ischemic stroke, and cardiovascular death, were also significantly decreased among GLP-1RA users.
Conclusion: In patients with elevated Lp(a), GLP-1RA therapy was associated with substantial reductions in mortality and cardiovascular events. These findings suggest potential cardioprotective effects of GLP-1RAs in a high-risk population with limited therapeutic options and support further prospective evaluation.
Summary written by lp-a.org from the published abstract; figures as published. Page updated 17 August 2026. Methods.